Read this company snapshot
Daily valuation snapshot
Wave Life Sciences Ltd. Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $3.46
- Market capitalization (USD)
- $681,786,685.5
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.5
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research WVE in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research WVE in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing WVE with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $3.46 |
| Market capitalization (USD) | $681,786,685.5 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.5 |
No matching rows. Clear the filter to see all records.
Read WVE's valuation metrics
Company size
Wave Life Sciences Ltd. Ordinary Shares's recorded market capitalization is $681,786,685.5. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
WVE's recorded price-to-book ratio is 1.5. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Wave Life Sciences Ltd. Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about WVE. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow WVE's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.